SCHEMBL244674

SCHEMBL244674

Cc1ccc(-c2cccc(C(=O)Cl)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.54
KMO O15229 1/20 0.48
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
HDAC8 Q9BY41 1/20 0.44
CSF1R P07333 1/20 0.44
FLT1 P17948 1/20 0.44
FLT3 P36888 1/20 0.44
UTS2R Q9UKP6 2/20 0.44
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44
PTPN5 P54829 1/20 0.44
RXRA P19793 2/20 0.44
RXRB P28702 2/20 0.44
RXRG P48443 1/20 0.44
MCL1 Q07820 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28032601 0.88 KMO (0.59) DHODHKMOLMNAGAAHDAC8
SCHEMBL726544 0.86 KMO (0.53) KMOMAPTCTDSP1LMNAGAA
SCHEMBL726087 0.86 KMO (0.56) DHODHKMOLMNAGAAHDAC8
SCHEMBL699008 0.84 KMO (0.67) DHODHKMOMAPTHDAC8RXRA
SCHEMBL30698052 0.84 KMO (0.67) DHODHKMOMAPTHDAC8RXRA
SCHEMBL121436 0.83 KMO (0.71) DHODHKMOLMNAGAARXRA
SCHEMBL4572428 0.83 NPC1 (0.56) DHODHKMOMAPTLMNAGAA
SCHEMBL28969693 0.83 RXRA (0.53) KMOHDAC8UTS2RRXRARXRB
Hydrogen Sulfide SCHEMBL27896825 0.82 KMO (0.64) DHODHKMOMAPTHDAC8RXRA
SCHEMBL23289052 0.81 DHODH (0.58) DHODHKMOMAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748412-B2 Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators ARGUSINA BIOSCIENCE INC. (KY) 2014-06-10 US disclosed
EP-2531198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS Argusina Inc. (US) 2012-12-12 EP disclosed
US-20120004198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2012-01-05 US disclosed
WO-2011094890-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2011-08-11 WO disclosed
WO-2011097300-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, GPR119 DHODH 3813/4885KMO 629/4885POLB 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.